Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents

• Egile Nagusiak: Anne Cecília Nascimento da Cruz (Egilea), Dalci José Brondani (Egilea), Temístocles I´talo de Santana (Egilea), Lucas Oliveira da Silva (Egilea), Elizabeth Fernanda da Oliveira Borba (Egilea), Antônio Rodolfo de Faria (Egilea), Julianna Ferreira Cavalcanti de Albuquerque (Egilea), Sylvie Piessard (Egilea), Rafael Matos Ximenes (Egilea), Blandine Baratte (Egilea), Stéphane Bach (Egilea), Sandrine Ruchaud (Egilea), Francisco Jaime Bezerra Mendonça Junior (Egilea), Marc-Antoine Bazin (Egilea), Marcelo Montenegro Rabello (Egilea), Marcelo Zaldini Hernandes (Egilea), Pascal Marchand (Egilea), Teresinha Gonçalves da Silva (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2019-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Fourteen arylsemicarbazone derivatives were synthesized and evaluated in order to find agents with potential anticancer activity. Cytotoxic screening was performed against K562, HL-60, MOLT-4, HEp-2, NCI-H292, HT-29 and MCF-7 tumor cell lines. Compounds <b>3c</b> and <b>4a</b>...